Literature DB >> 3038237

Effects of cations on binding, in membrane suspensions, of various opioids at mu-sites of rabbit cerebellum and kappa-sites of guinea-pig cerebellum.

H W Kosterlitz, S J Paterson, L E Robson, J R Traynor.   

Abstract

At the mu-sites of rabbit cerebellum, NaCl, LiCl, KCl, choline chloride and MnCl2 were tested for potentiation and inhibition of the binding of several opioids. Naloxone, (-)-bremazocine and diprenorphine are mu-antagonists in pharmacological assays and their binding is potentiated by the lower concentrations and inhibited by the higher concentrations of NaCl. The binding of the agonists [3H]-[D-Ala2, MePhe4, Gly-ol5]enkephalin and [3H]-dihydromorphine is inhibited. MnCl2 potentiates the binding of the agonist [3H]-[D-Ala2, MePhe4, Gly-ol5]enkephalin but not the binding of the antagonists. The thresholds of inhibition and slopes of the dose-response curves for inhibition by MnCl2 and LiCl vary. This finding may indicate that potentiating effects of MnCl2 and LiCl are masked by simultaneous inhibition. At the kappa-sites of guinea-pig cerebellum, NaCl, KCl and MnCl2 inhibit the binding of [3H]-dynorphin A (1-8), [3H]-dynorphin A (1-9), [3H]-(-)-bremazocine, [3H]-tifluadom, and [3H]-diprenorphine. NaCl also causes a small potentiation of the binding of [3H]-diprenorphine, which is a kappa-agonist in the guinea-pig myenteric plexus but a kappa-antagonist in the rabbit vas deferens. The slopes of the inhibitory dose-response curves and the thresholds of inhibition vary with the different ligands. Therefore some potentiating effects may have been masked. The results support the view that NaCl, and perhaps LiCl, but not KCl and choline chloride, potentiate the binding of mu-antagonists but not the binding of mu-agonists. It is not yet possible to decide whether, at the kappa-site, there is a similar differentiation of the binding of agonists and antagonists.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3038237      PMCID: PMC1853519          DOI: 10.1111/j.1476-5381.1987.tb10298.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

1.  Unexpected antagonism in the rat vas deferens by benzomorphans which are agonists in other pharmacological tests.

Authors:  M G Gillan; H W Kosterlitz; J Magnan
Journal:  Br J Pharmacol       Date:  1981-01       Impact factor: 8.739

2.  Bremazocine is an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors in the guinea-pig myenteric plexus.

Authors:  A D Corbett; H W Kosterlitz
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

3.  Control by cations of opioid binding in guinea pig brain membranes.

Authors:  S J Paterson; L E Robson; H W Kosterlitz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

4.  Kappa-binding and degradation of [3H]dynorphin A (1-8) and [3H]dynorphin A (1-9) in suspensions of guinea pig brain membranes.

Authors:  M G Gillan; L E Robson; A T McKnight; H W Kosterlitz
Journal:  J Neurochem       Date:  1985-10       Impact factor: 5.372

5.  Opioid binding sites of the kappa-type in guinea-pig cerebellum.

Authors:  L E Robson; R W Foote; R Maurer; H W Kosterlitz
Journal:  Neuroscience       Date:  1984-06       Impact factor: 3.590

6.  Spectrum of the mu, delta- and kappa-binding sites in homogenates of rat brain.

Authors:  M G Gillan; H W Kosterlitz
Journal:  Br J Pharmacol       Date:  1982-11       Impact factor: 8.739

7.  Multiple opiate binding sites in the central nervous system of the rabbit. Large predominance of a mu subtype in the cerebellum and characterization of a kappa subtype in the thalamus.

Authors:  J C Meunier; Y Kouakou; A Puget; C Moisand
Journal:  Mol Pharmacol       Date:  1983-07       Impact factor: 4.436

  7 in total
  6 in total

1.  Opioid receptor-mediated control of acetylcholine release in human neocortex tissue.

Authors:  T J Feuerstein; O Gleichauf; D Peckys; G B Landwehrmeyer; R Scheremet; R Jackisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

2.  Inability of an opioid antagonist lacking negative intrinsic activity to induce opioid receptor up-regulation in vivo.

Authors:  B J Morris; M J Millan
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

3.  N,N-diallyl-tyrosyl substitution confers antagonist properties on the kappa-selective opioid peptide [D-Pro10]dynorphin A(1-11).

Authors:  J E Gairin; H Mazarguil; P Alvinerie; C Botanch; J Cros; J C Meunier
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

4.  Inhibition by cations of antagonist binding to histamine H1-receptors: differential effect of sodium ions on the binding of two radioligands.

Authors:  J M Treherne; J S Stern; W J Flack; J M Young
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

5.  Effect of sodium on [3H]ethylketocyclazocine binding to opioid receptors in frog brain membranes.

Authors:  S Benyhe; T Farkas; M Wollemann
Journal:  Neurochem Res       Date:  1989-03       Impact factor: 3.996

6.  Alkylation with beta-funaltrexamine suggests differences between mu-opioid receptor systems in guinea-pig brain and myenteric-plexus.

Authors:  T G Franklin; J R Traynor
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.